Compare United Microelectronics Corp (UMC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? United Microelectronics Corp trades at $21.15 (market cap $51.00B), while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× United Microelectronics Corp's market cap, and United Microelectronics Corp pays a 2.03% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| UMC | VRTX | |
|---|---|---|
Market Cap | $51.00B | $121.95B |
Sector | Technology | Health |
52-Week High | $28.02 | $529.59 |
52-Week Low | $6.58 | $366.54 |
Enterprise Value | $48.57B | $116.69B |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UMC trades at $21.19, down 0.28% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains a net income margin of 20.25%. Recent news highlights mass production of silicon photonics ICs and strong June 2026 sales growth of 22.85% year-over-year.
Outlook is supported by earnings beats and specialty technology demand, but risks include valuation above sector peers and competitive pressures. Analysts are mixed with 26.67% buy ratings, suggesting cautious optimism amid solid execution.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
